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Summary
We have investigated the efficacy of conditioning skin Langerhans cells
(LCs) with agents to promote tolerance and reduce inflammation, with the
goal of improving the outcomes of antigen-specific immunotherapy. Topical
treatments were assessed ex vivo, using excised human breast skin main-
tained in organ bath cultures, and in vivo in healthy volunteers by analysing
skin biopsies and epidermal blister roof samples. Following topical treat-
ment with a corticosteroid, tumour necrosis factor-a levels were reduced in
skin biopsy studies and blister fluid samples. Blister fluid concentrations of
monocyte chemoattractant protein-1, macrophage inflammatory proteins -
1a and 1b and interferon-c inducible protein-10 were also reduced, while
preserving levels of interleukin-1a (IL-1a), IL-6, IL-8 and IL-10. Steroid pre-
treatment of the skin reduced the ability of LCs to induce proliferation,
while supernatants showed an increase in the IL-10/interferon-c ratio.
Phenotypic changes following topical steroid treatment were also observed,
including reduced expression of CD83 and CD86 in blister-derived LCs, but
preservation of the tolerogenic signalling molecules immunoglobulin-like
transcript 3 and programmed death-1. Reduced expression of HLA-DR,
CD80 and CD86 were also apparent in LCs derived from excised human
skin. Topical therapy with a vitamin D analogue (calcipotriol) and steroid,
calcipotriol alone or vitamin A elicited no significant changes in the parame-
ters studied. These experiments suggest that pre-conditioning the skin with
topical corticosteroid can modulate LCs by blunting their pro-inflammatory
signals and potentially enhancing tolerance. We suggest that such modula-
tion before antigen-specific immunotherapy might provide an inexpensive
and safe adjunct to current approaches to treat autoimmune diseases.
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Introduction
The skin has been used for over two centuries as a route
of antigen administration to induce immune responses.1
More recently, the skin has been recognized as a route to
down-regulate unwanted immune responses including
allergy and autoimmunity.2,3 The attraction of the dermal
route is that it is easy and convenient to access and the
skin is rich in dendritic cells (DCs), particularly in the
upper layers.4 Although some success has been achieved
with desensitization in allergy using the intradermal5 or
subcutaneous6 routes of antigen administration, the abil-
ity of tolerance protocols to down-regulate autoimmune
responses has been modest in the published literature.7–12
Tolerogenic DCs undoubtedly exist in the skin,13–17
presumably with a role in promoting self-tolerance, as
originally proposed by Steinman and Nussenzweig.18 Sev-
eral subsets of DCs are capable of uptake and presenta-
tion of self-antigen.19 Recently a specific tolerogenic
CD14+ CD141+ DC subset has been identified in
Abbreviations: CD, cluster of differentiation; cDNA, complementary deoxyribonucleic acid; DC, dendritic cell; IFN-c, interferon-
c; IL, interleukin; ILT3, immunoglobulin-like transcript 3; LC, Langerhans cell; MECLR, mixed epidermal cell lymphocyte reac-
tion; PBMCs, peripheral blood mononuclear cells; PD-1, programmed death-1; TNF-a, tumour necrosis factor-a
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humans.20 The role of epidermal Langerhans cells (LCs)
in this process has been controversial, with some confu-
sion arising from the existence of dermal langerin-positive
DCs; however, the evidence from murine studies supports
their tolerogenic potential, at least in the uninflamed
state.21–23 Current evidence suggests that, in the absence
of pro-inflammatory signals, resting antigen presenting
cells in many sites, including the skin, present self-antigen
in a pro-tolerogenic manner and indeed, this may be part
of the general system of maintenance of peripheral toler-
ance to self.24 It therefore seems likely that the limited
tolerance induction resulting from skin antigen adminis-
tration to date is not due to a lack of uptake by DCs in
the skin, but is a result of the failure to selectively target
those with the most tolerogenic potential, a pro-inflam-
matory effect of the antigen administration process on
immature DCs or dissemination of the antigen to distant
sites (lymph nodes, spleen, bone marrow) where tolerance
is not sufficiently promoted.
To overcome these limitations, and develop a method
of skin administration that can reliably induce antigen-
specific tolerance, we reasoned that conditioning of the
LCs with agents to promote tolerance and reduce inflam-
mation might improve outcomes. The accessibility of the
skin permits conditioning with topical agents, so reducing
the effects of systemic exposure. The optimal induction of
tolerance might then be expected if successful pre-condi-
tioning was combined with subsequent antigen adminis-
tration into the superficial layers of the skin. The
outermost skin layer, the epidermis, is the most accessible
for conditioning treatment, is richest in DCs25 and is
likely to facilitate localized conditioning of local DCs
without excessive dosing of the systemic immune system.
Furthermore, by using a topical treatment to condition
all DCs in the local area, we may circumvent the need to
subsequently target the ‘most tolerogenic’ DCs with an
antigen immunotherapy.
Local conditioning of DCs for tolerance is made more
feasible in skin rather than other sites (e.g. gut, nasal
epithelium), as not only can the site of conditioning
treatment and antigen administration be accurately tar-
geted, but the skin can be sampled to monitor the effects
of treatment. Here we report the examination of a range
of potential conditioning therapies in human skin, as well
as more extensive studies of the most promising of these
(topical corticosteroid), using a combination of ex vivo
and in vivo approaches.
Materials and methods
Subjects and human samples
The studies were conducted in accordance with the Inter-
national Conference on Harmonization/World Health
Organization Good Clinical Practice standards. All sub-
jects provided written informed consent before enrolment
in the study, according to the Declaration of Helsinki
(revision 2013).
Skin biopsies for the in vivo assessment of the topical
immunomodulatory treatment. This study, approved by
the Bath Research Ethics Committee, UK, recruited
healthy volunteers aged 18–50 years with no history of
skin conditions and no current or recent use of topical or
systemic corticosteroids, vitamin D preparations or any
other potentially immunomodulatory therapy. One group
of untreated subjects had two 4-mm skin punch biopsies
removed from the medial aspect of one arm (Kai Medi-
cal, Seki, Japan). A second group of subjects received two
50-ll intradermal injections of 09% saline, and a skin
punch biopsy was taken from the treatment site 6 or 9 hr
later. A third group applied Dovobet ointment [cal-
cipotriol + betamethasone, 0005% weight/weight
(w/w) + 005% w/w; Leo Pharma Inc., Ballerup, Den-
mark], every 12 hr for 4 days, to the medial aspect of their
arm before receiving two 50-ll intradermal injections of
09% saline. Each treatment site was then punch biopsied
6 hr later. Skin biopsy samples were immediately snap fro-
zen in liquid nitrogen and stored for future use at 80°.
Skin organ bath culture for the ex vivo assessment of the
topical steroid treatment. Skin samples were obtained from
female patients aged 19–82 years, following mastectomy
or breast reduction. Skin without obvious pathological
findings that was surplus to diagnostic histopathology
requirements was excised and transported to the labora-
tory on ice in Dulbecco’s modified Eagle’s medium (In-
vitrogen, Paisley, UK). The study received full ethical
approval from South East Wales Research Ethics Com-
mittee, UK.
Subcutaneous adipose tissue was removed by blunt dis-
section to yield full-thickness skin, which was topically
treated with DiproSone cream (0005% w/w betametha-
sone, as dipropionate; MerckSharp&Dohme Ltd., Hod-
deson, UK) or PBS (Invitrogen). Without removal of the
steroid or PBS, the skin was cut into smaller circular
samples (diameter of 08 cm) and cultured at the air–liq-
uid interface on Transwell (Lifesciences, Tewksbury,
MA) inserts in 24-well plates containing Dulbecco’s mod-
ified Eagle’s medium supplemented with 100 U/ml of
penicillin and 100 lg/ml of streptomycin (Invitrogen) at
37° and 5% volume/volume (v/v) CO2/95% (v/v) air.
After a 24-hr incubation the skin was removed from cul-
ture and immersed in enzyme solution containing Dis-
pase II (Roche, Burgess Hill, UK), collagenase I and
DNase I (Invitrogen) for 1 hr at 37°. Epidermal sheets
were mechanically separated from the dermis and pro-
cessed to obtain an epidermal cell suspension.
Blister formation for the in vivo assessment of the topical
steroid treatment. This study, approved by the Bath
Research Ethics Committee, UK (Part 1), and South West
3 Research Ethics Committee, UK (Part 2) involved
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healthy volunteers aged 18–45 years with no history of
skin conditions and no current or recent use of topical or
systemic steroid, vitamin D preparation or any other
potentially immunomodulatory therapy.
Subjects in the Part 1 study group applied topical treat-
ment, 12 hr for 4 days, followed by intradermal injection
of 50 ll of 09% saline to the medial aspect of the arm.
Blister formation was performed 6–18 hr after injection.
Five sub-groups were created, depending on the topical
treatment that was applied before injection: (I)
DiproSone cream (005% w/w betamethasone as
dipropionate, MerckSharp & Dohme Ltd.); (II) Dovobet
ointment (calcipotriol + betamethasone dipropionate,
0005% w/w + 005% w/w, Leo Pharma Inc.), (III)
Dovonex ointment (calcipotriol 0005% w/w, Leo
Pharma Inc.), (IV) Retin-A gel (tretinoin 001% w/w,
Janssen-Cilag Ltd., High Wycombe, UK) and (V) Control
group – saline injection only, before the blister forma-
tion, without a previous topical treatment.
Participants in Part 2 of the study applied DiproSone
cream, every 12 hr for 4 days, to the medial aspect of
one arm (with the other arm left untreated) before receiv-
ing two 50 ll intradermal injections of 09% saline, one
in the pre-treated arm and one in the untreated arm.
Blister formation was performed 6–18 hr after injections,
in both arms.
Skin suction blisters were performed by gradually
applying negative pressure (up to 50 kPa) from a suction
pump machine VP25 (Eschmann, Lancing, UK) through
a suction blister cup with a 15-mm hole in the base
(UHBristol NHS Foundation Trust Medical Engineering
Department, Bristol, UK) for 2–6 hr until a unilocular
blister had formed within the cup. The blister fluid was
aspirated after blister formation and stored at 20° for
cytokine measurement at a later date. The blister roof was
removed using a surgical blade (Swann Morton Ltd.,
Sheffield, UK) and used to prepare an epidermal cell sus-
pension the same day (see below).
Preparation of epidermal cell suspension from skin organ
bath culture or blister roofs. Epidermal sheets obtained
from the skin organ bath culture or blister roof were
transferred into 025% w/v trypsin solution (Sigma-
Aldrich, Poole, UK) in PBS for 30 min at 37°. After the
incubation, epidermal cells were re-suspended in 0025%
(w/v) DNase I in 10% (v/v) fetal calf serum (PAA,
Pasching, Austria) in PBS for 1 hr. Epidermal cell sus-
pensions were filtered through a 70-lm cell strainer and
subsequently stained for flow cytometry analysis or used
in the mixed epidermal cell lymphocyte reaction
(MECLR).
Peripheral blood samples. Blood samples were collected
from healthy volunteers aged 18–55 years, after full ethi-
cal approval by Research Ethics Committee for Wales,
Bath Research Ethics Committee and South West 3
Research Ethics Committee, UK.
Polymerase chain reaction (PCR)
Ribonucleic acid (RNA) was extracted from frozen skin
biopsy samples using the AurumTM Total RNA Mini Kit
(Bio-Rad Laboratories, Hercules, CA) according to the
manufacturer’s Spin Protocol for Animal and Plant Tis-
sue. Depending on the quantity of RNA obtained from
the skin biopsy sample, cDNA synthesis was performed
using either the SuperScriptTM First-Strand Synthesis Sys-
tem for real-time PCR (Invitrogen) or the SuperScript
VILOTM cDNA Synthesis Kit (Invitrogen), again accord-
ing to the manufacturer’s protocols. Quantitative PCR
was performed using Platinum Quantitative PCR Super-
Mix-UDG (Invitrogen) and TaqMan Gene Expression
Assays Hs00174128_m1, for tumour necrosis factor-a
(TNF-a), and Hs00174086_m1, for interleukin-10 (IL-10)
(Applied Biosystems/Life Technologies, Paisley, UK) in a
7500 Realtime PCR Systems machine (Applied Biosys-
tems/Life Technologies). Reactions contained 125 ll of
the SuperMix-UDG solution, 005 ll of ROX reference
dye and 125 ll of primer probe (the assay gene) and
were made up to a total volume of 25 ll with the cDNA
sample and diethylpyrocarbonate-treated water. Samples
were analysed in triplicate for each assay gene and for the
endogenous control gene, non-primer limited and 6-car-
boxyfluorescein-labelled glyceraldehyde-3-phosphate
dehydrogenase (Applied Biosystems/Life Technologies).
Experiments were conducted using the standard curve
method.
Mixed epidermal cell lymphocyte reaction and mixed
lymphocyte reaction
Peripheral blood mononuclear cells (PBMCs) were iso-
lated on Ficoll-Paque Plus (1077  0001 g/ml, +20°; GE
Healthcare Biosciences, Uppsala, Sweden) gradient by
centrifugation from the peripheral blood of healthy
donors.
Epidermal cells (50 000 live cells/well, containing DCs)
or irradiated PBMCs (12 Rad/s; 200 000 live cells/well),
were incubated with allogeneic PBMCs (200 000 live
cells/well) in 200 ll/well of 10% (v/v) human AB serum
(PAA, Pasching, Austria) in RPMI-1640 (Gibco, Paisley,
UK) supplemented with 05 mM of L-glutamine, 100
U/ml of penicillin, 100 lg/ml of streptomycin and
025 lg/ml of amphotericin B (Gibco) in a 96-well plate,
at 37° in 5% CO2/95% (v/v) air. After 96 hr of culture,
100 ll of supernatant was collected and stored at 20°
for cytokine detection at a later date. [3H]Thymidine
(1 lCi; Perkin-Elmer, Cambridge, UK) was added to each
well and the incorporation of radioactivity was measured
after 16 hr using a MicroBeta2 plate scintillation counter
(Perkin-Elmer).
Co-culture of epidermal cells with allogeneic donor
PBMCs is referred to as MECLR and the co-culture of
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irradiated PBMCs with allogeneic donor PBMCs is
referred to as mixed lymphocyte reaction.
Cytokine measurements
Cytokines, interferon-c (IFN-c) and IL-10, in the super-
natants of the MECLR driven by DCs originating from
ex vivo skin cultures, were measured by ELISA (eBio-
sciences, Hatfield, UK).
Cytokines from both blister fluid samples and from the
supernatants from MECLR driven by DCs originated
from blister roofs, were measured by using a human Mil-
liplex cytokine 96-well plate assay MPXHCYTO-60K-26
(Merck-Millipore, Billerica, MA), analysed using Luminex
100TM Luminex Corp, Austin, MI).
Flow cytometry analysis
The following monoclonal antibodies were used for the
analysis of DCs: eFluor450-anti-human-CD1a (clone
HI149), FITC-anti-human-CD40 (clone 5C3), phycoery-
thrin-anti-human-CD83 (clone HB15e), eFluor710-anti-
human-CD83 (clone HB15e), phycoerythrin-anti-human-
immunoglobulin-like transcript 3 (ILT3; clone ZM4.1),
PECy7-anti-human-CD11c (clone 3.9) all from eBio-
sciences; biotin-anti-human-CD80 (clone L307.4, BD
Pharmingen, Oxford, UK) with streptavidin peridinin
chlorophyll protein-Cy5.5 (eBiosciences) or anti-biotin
Pacific Orange (Invitrogen), allopycocyanin-anti-human-
CD86 (clone 2231 FUN-1), peridinin chlorophyll protein-
Cy5.5-anti-human-HLA-DR (clone G46-6), both from
BD Pharmingen, Oxford, UK; Alexa Fluor 488 anti-hu-
man programmed death-1 (PD-1; clone EH12.2H7) from
Biolegend, London, UK and near IR fixable Live/Dead
stain (Invitrogen, Paisley, UK). After gating on live and
single cells, LCs were defined as CD1a+ HLA-DR+ cells.
21
The cells were analysed on a FACS Canto II flow
cytometer (BD Biosciences) and analysed with FLOWJO
software version 8.8.6 (Leland, Stanford, CA).
Confocal imaging
Participants applied DiproSone cream, twice daily for
4 days, to the medial aspect of one arm with the other
arm left untreated. Epidermal sheets originated from blis-
ter roofs were mounted on silane prep slides (Sigma-
Aldrich), fixed with 2% paraformaldehyde (Sigma-
Aldrich) for 15 min, permeabilized with 01% Triton X-
100 (Sigma-Aldrich) and stained with a one-step mono-
clonal anti-human, mouse Langerin-Alexa Fluor 488
(Dendritics, Lyon, France), after blocking with human Fc
receptor binding inhibitor (eBiosciences). Cover glass was
adhered over the stained blister sheets with Prolong Gold
(Invitrogen, Paisley, UK), and the slides were placed hori-
zontal in the slides box and left to adhere in the fridge
(2–8°) overnight.
Confocal Images were acquired using a Radiance 2000-
MP CLSM mounted on a Nikon TE 300 inverted micro-
scope (Bio-Rad Laboratories Ltd, Hertfordshire, UK).
Dual channel images were collected (1024 9 1024 pixels)
with the 910 CFI Plan Fluor; N.A. 03. Alexa488 was
detected using 488 nm excitation/500 nm LP-HQ 530 nm
SP emission and including a transmission image, which
enabled evaluation of tissue integrity and presentation
(for counting, pixel calibration was set at 104 lm). Next
analysis was conducted using the METAMORPH OFFLINE
software (version 7.6.00) (MDS Analytical Technology,
Sunnyvale, CA) to detect and count ‘Langerhan’ objects.
The approach was based on a threshold detection of a cell
object and an object was designated a Langerhan object if
it was > 3 pixels to ensure that objects counted were cell
bodies only within a random square that had a minimum
of 400 pixels and a maximum of 800 pixels on centroid
(x, y). This detection approach was applied to all epider-
mal sheets studied.
The numbers of Langerin-stained DCs were then calcu-
lated in 160 000-pixel squares from the four sides of each
sample and the average number of LCs from the four
sides of the sample was compared between control and
matching steroid-treated skin specimens. The numbers
were calculated in 1 mm2 by using a conversion factor
from pixels to 1 mm2.
Statistics
The Wilcoxon Signed Rank test and the Mann–Whitney
U-test were performed to test differences between paired
and unpaired measurements, respectively. One sample
t-test was used to test the significance of the percentage
of the change in relation to the baseline value. For com-
parison of three or more samples one-way analysis of
variance was used. Analysis was performed using Prism
GRAPHPAD 4.0a (GraphPad Software, La Jolla, CA, USA)
for Macintosh. P-values of < 005 were considered signifi-
cant. Results were expressed as mean  standard devia-
tion (SD).
Results
Intradermal injection of 50 ll of isotonic saline in healthy
volunteers was found to induce local pro-inflammatory
cytokine release, as demonstrated by an increase in TNF-
a mRNA (Fig. 1a). This effect was abrogated by pre-con-
ditioning of the skin with a topical corticosteroid (be-
tamethasone dipropionate) and a vitamin D analogue
(calcipotriol), which led to significant reduction of the
TNF-a expression (P = 004, n = 8, Fig. 1b). Interleukin-
10 mRNA was detected in three out of eight individuals
both before and after 4 hr of topical steroid and vitamin
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D therapy, suggesting that IL-10 production was unaf-
fected by topical treatments (Fig. 1b).
To determine if the cytokine changes in whole skin fol-
lowing steroid therapy reflected changes in LC function, a
human skin organ culture system was used. Excised breast
skin from mastectomy procedures was treated with or
without topical steroids and was subsequently cultured
overnight before enzyme digestion, separation of the epi-
dermal layer and preparation of an epidermal cell suspen-
sion. As expected, the epidermal cell suspensions contained
a high number of dead cells (differentiated keratinocytes),
but a CD1a+ population was consistently identified among
the live cell population (see Supplementary material,
Fig. S1a). CD1a+ HLA-DR+ and CD1a+ Langerin+ DCs
represented 1–2% of the live epidermal cells (see Supple-
mentary material, Fig. S1b) with similar percentages in
both untreated and corticosteroid-treated samples (see
Supplementary material, Fig. S1c). The epidermal cell pop-
ulation showed significant reduction in HLA-DR, CD80
and CD86, with a trend towards reduction in CD83 levels
and a trend towards an increase in PD-1, following topical
steroid therapy. This is consistent with a more immature or
tolerogenic phenotype (Fig. 2a). Consistent with this, there
was a reduction in the ability of the epidermal cell suspen-
sions to stimulate an MECLR (Fig. 2b). Supernatants from
these cultures demonstrated an increase in the IL-10/IFN-c
ratio (Fig. 2c), additionally consistent with a more pro-
tolerogenic state in the LCs.
The skin organ culture methodology permits the effects
of topically applied corticosteroid therapy to be studied
in human skin, but may not be wholly reflective of the
effects when applied in vivo. We therefore developed a
modification of the induced skin blister technique,
described by Reed et al.,26 in which topical corticosteroid
therapy was applied to arm skin in vivo, followed by suc-
tion blister formation and an aspiration of blister fluid to
sample interstitial cytokine and chemokine levels.27 Epi-
dermal cells from excised blister roofs were also used to
study LC function. Fifteen individuals were studied,
including seven in whom blisters were induced in both
arms with one arm steroid pre-treated and another (con-
trol arm) left untreated. Blister cytokine levels in individ-
uals in which paired samples from two arms were studied
(n = 7), showed differences in blister fluid levels of
macrophage inflammatory protein-1a (P = 003) and
trends (P = 005) towards differences in macrophage-in-
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Figure 1. Cytokine mRNA levels in skin biopsies. (a) Tumour necrosis factor-a (TNF-a) expression by RT-PCR in skin biopsy samples taken
from untreated subjects and from subjects 6–9 hr following intradermal injection of 005 ml 09% saline (n = 7 and 10, respectively; P = 0005).
(b) TNF-a and interleukin-10 (IL-10) expression by RT-PCR in skin biopsy samples taken from subjects 6 hr following intradermal injection of
005 ml 09% saline without (n = 8) and with 4 days of 12 hourly topical vitamin D/steroid (calcipotriol + betamethasone, 0005% w/w + 005%
w/w) pre-treatment (n = 8); P = 004 and non-significant for TNF-a and IL-10, respectively. Expression was shown as relative to the expression
of the endogenous control gene GAPDH for glyceraldehyde-3-phosphate dehydrogenase. Each point represents one subject. *P < 005,
**P < 001.
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flammatory protein-1b and TNF-a (data not shown).
These differences were not apparent with the unpaired
samples alone. The samples were pooled for greater
power (n = 15). The reduction in TNF-a levels in the
skin biopsy studies (Fig. 1) was replicated in the blister
fluid following corticosteroid treatment for 4 days
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Figure 2. Phenotype and functional capacity of Langerhans cells (LCs) with and without ex vivo exposure to betamethasone dipropionate cream
(005% w/w) in the human skin organ culture. Comparisons were made to untreated skin from the same skin donor (baseline). (a) Percentage of
change in mean fluorescence intensity (MFI) measured by flow cytometry, of the HLA-DR (n = 9, P = 0002), CD80 (n = 6, P = 0016), CD86
(n = 6, P = 005), CD83 (n = 6, ns) and programmed death 1 (PD-1); n = 3, ns) is shown in the bar charts, each representing the skin sample
from the individual donor (dotted line across histograms marks the mean). Representative examples of flow cytometry histograms are shown
below (black line – untreated, grey line – steroid-treated, solid grey – unstained control). (b) Proliferation in the mixed epidermal cell lympho-
cyte reaction (MECLR), expressed as proliferation index, i.e. ratio of the MECLR/peripheral blood mononuclear cell (PBMC) [3H]thymidine
uptake (n = 9, P = 003). Baseline responder PBMC proliferation was 459  463 cpm. (c) Cytokine profile in the MECLR, expressed as the ratio
of interleukin-10 (IL-10) to interferon-c (IFN-c) measured in the supernatants of MECLRs (n = 9, P = 002). Mean absolute values: IFN-c
untreated 1928  2656 pg/ml, steroid-treated 1224  1804 pg/ml, IL-10 untreated 803  958 pg/ml, steroid-treated 507  444 pg/ml.
*P < 005; **P < 001; ns, not statistically significant.
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(Fig. 3a). Topical corticosteroid also significantly reduced
blister interstitial fluid levels of the chemokines monocyte
chemoattractant protein-1, macrophage inflammatory
proteins 1a and 1b and IFN-c-inducible protein 10
(Fig. 3a), while preserving levels of IL-1a, IL-6, IL-8,
IL-10 and granulocyte colony-stimulating factor (Fig. 3b).
Epidermal cells isolated from blister roofs were up to
10-fold more potent at stimulating an MECLR compared
with the skin-organ-bath-derived cells, presumably due to
the reduced exposure to in vitro culture. As few as 500
epidermal cells (comprising around 10 DCs) were consis-
tently able to stimulate an MECLR (Fig. 4a). Consistent
with skin organ cultures, corticosteroid pre-treatment of
the skin reduced the ability to induce an MECLR. This
effect was apparent in all volunteers, including those in
whom blisters were obtained from both arms, so provid-
CD 83
0 102 103 104 105
HLA-DR
0
20
40
60
80
100
%
 o
f m
ax
0 102 103 104 105
0 102 103 104 105
0 102 103 104 105
0 102 103 104 105
0
20
40
60
80
100
0
20
40
60
80
100
%
 o
f m
ax
%
 o
f m
ax
Control Steroid
0
5
10
15
20
(b) (c)
M
EC
LR
 p
ro
life
ra
tio
n 
in
de
x
*
Control Steroid
0·0
0·5
1·0
1·5
5
10
15
M
EC
LR
 IL
-1
0/
IF
N-
 
ra
tio
γ
*
PD-1
0
20
40
60
80
100
%
 o
f m
ax
CD 80 
CD86
0
20
40
60
80
100
%
 o
f m
ax
Figure 2. Continued
ª 2015 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 146, 411–422 417
Topical steroid promotes tolerance in human skin
ing an internal control (Fig. 4b) and confirming the con-
sistency of the effect. It is unlikely that this was simply a
result of the depletion of LCs following steroid therapy as
the overall numbers of epidermal cells obtained were sim-
ilar (see Supplementary material, Fig. S2), as previously
observed in the human skin organ culture model (see
Supplementary material, Fig. S1). In addition, confocal
microscopy did not show any difference in LC density
(Fig. 4c) Phenotypic changes in blister-derived LCs fol-
lowing topical treatment with corticosteroid included
reduced expression of CD83 and CD86 in CD1a+ cells,
with preservation of the tolerogenic signalling molecule
ILT3 (Fig. 5). In contrast to the excised human skin cul-
ture model, no difference in HLA-DR or CD80 was
detected in the human skin blister system, which may be
related to the different steroid treatment regimens in
these two experimental systems (4 days versus 1 day).
To determine whether other topical agents could have
a similar effect on LC phenotype and function, the blister
cell experiments were repeated using a vitamin D ana-
logue (calcipotriol), vitamin D analogue plus steroid, and
vitamin A (tretinoic acid), which did not result in any
significant changes in the parameters studied (see Supple-
mentary material, Fig. S3).
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Figure 3. Cytokine profile in blister fluid with and without previous in vivo exposure to betamethasone dipropionate cream (005% w/w). (a)
Statistically significant changes in the level of tumour necrosis factor-a (TNF-a) (P = 001), monocyte chemoattractant protein-1 (MCP-1)
(P = 0001), macrophage inflammatory proteins MIP-1a (P = 003), MIP-1b (P = 004) and interferon-c inducible protein 10 (IP-10) (P = 004)
were observed after topical steroid treatment for 4 days. Analysis was performed using a human Milliplex cytokine 96-well plate assay. (b) Four
days of topical steroid treatment did not cause significant changes in the levels of granulocyte colony-stimulating factor (G-CSF), interleukin-10
(IL-10), IL-12p40, IL-1a, IL-6 and IL-8. n = 15. *P < 005, **P < 001.
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Discussion
This study has shown that injection of an inert liquid
(isotonic saline) in volumes as small as 50 µl into human
skin induces increased expression of TNF-a with the
potential for pro-inflammatory effects, which may antago-
nize the beneficial effects the intradermally delivered
immunomodulating agent administered to achieve toler-
ance. This change was negated by conditioning the skin
with topically applied corticosteroids, which have been
shown to be as effective as steroid plus vitamin D ana-
logue. In addition, topical corticosteroids induced multi-
ple changes that might be expected to promote tolerance
including a reduction in HLA-DR, CD83 and CD86
expression in LCs, and reduced proliferation and IFN-c
production in T cells activated by these LCs. Interleukin-10
production and the expression of the tolerogenic co-stim-
ulatory molecule ILT3 were not affected by steroid ther-
apy, whereas there was a trend towards increase in PD-1.
Additional changes in the skin environment were
observed, including reduction in chemokine expression
including monocyte chemoattractant protein-1, macro-
phage inflammatory proteins and IL-10. No significant
effect on any of these parameters was seen with topical
vitamin D analogue (calcipotriol) or vitamin A alone
(isotretinoin).
Strengths of the current study include the use of
in vivo studies and live human skin-derived cells, concor-
dance of data from different techniques (skin biopsies,
skin organ bath cultures, blister fluid studies) and the use
of control cells from the same subject in later experi-
ments. A potential weakness is the fact that due to
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Figure 4. Functional capacity of Langerhans
cells (LCs) with and without previous in vivo
exposure to betamethasone dipropionate cream
(005% w/w). (a) Proliferation in mixed epi-
dermal cell lymphocyte reaction (MECLR)
stimulated by a variable number of untreated
epidermal cells (ECs), compared with the pro-
liferation in mixed lymphocyte reaction (MLR)
from the same donor–responder pair. Data
from previous experiments (not shown) indi-
cated a low proliferation rate of epidermal cells
measured by 3[H]thymidine uptake (below
100 cpm). (b) Proliferation in the MECLR
expressed as ratio of the MECLR/MLR from
the same donor–responder pair; whole group
(n = 14, P = 0016), group with the internal
control (n = 7, P = 0008). Baseline responder
peripheral blood mononuclear cell proliferation
was 403  267 cpm in the group with the
internal control and 495  386 cpm in the
whole group. Number of ECs per well was
15 000. (c) Analysis of the LCs in the blister
roof by confocal microscopy: langerin-stained
epidermal dendritic cells (DCs) (green spots)
are shown in the two upper figures; lower fig-
ure: exposure to betamethasone dipropionate
cream (005% w/w) did not change the mean
number of langerin-stained DCs in the blister
roof (n = 8, ns). The number of langerin-
stained DCs was calculated in 1 mm2. The
mean number of LCs was compared between
control and steroid-treated skin specimens
from the same donor. Lines in the graph are
connecting the data from the same individual
(untreated and steroid treated). *P < 005.
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limited cell numbers, LCs were not purified, so other cell
types such as keratinocytes may also have contributed to
the functional changes. In addition, although many
potentially relevant changes following steroid therapy
were defined, the key mechanism of action resulting in a
reduction in induced T-cell proliferation and IFN-c pro-
duction was not identified. Topical steroid therapy has
previously been shown to reduce T-cell proliferation
induced by skin cells extracted from treated skin, but the
phenotype of the cells and the regulatory potential was
not examined.28 The phenotype of the steroid-treated LCs
observed in the current study – low CD80, CD83, CD86
HLA-DR with preserved ILT3 and trend towards increase
in PD-1, is similar to that reported by others to be associ-
ated with tolerogenic DCs.29–31
Our method of LC enumeration in epidermal sheets
employed an automated pixel recognition technique (see
Materials and methods) designed to objectively compare
numbers of LC between samples. Only cells with more
than a minimum pixel density were counted and as a
result the absolute number of LCs per mm2 was in some
cases lower than previously reported in studies of epider-
mal sheets.27,32 However, comparison between samples
enumerated consistently by this approach did not reveal
any significant change in LC number following in vivo
steroid pre-treatment, and this was consistent with the
findings from our ex vivo treatment studies enumerated
by flow cytometry. Note that previous studies suggest that
saline injection does not affect LC number in epidermal
sheets derived from suction blisters, but the suction blis-
ter method itself results in approximately 30% fewer LCs
than in the epidermal sheets derived from punch biop-
sies.32
We were surprised that neither topical treatment with
vitamin D nor vitamin A appeared to promote a regula-
tory phenotype in LCs. Vitamin D has been reported to
induce regulatory potential when used to treat psoriatic
skin,33 when used to locally target dermal DCs in skin
explants34 and in combination with steroid to treat
mature monocyte-derived DCs.29 DCs used in the skin
blister model are mainly of epidermal origin and there-
fore likely to exhibit an immature phenotype.21–23 This
and the fact that they are derived from non-inflamed skin
may be an explanation for the lack of vitamin D effect. It
remains possible that these agents could be of benefit, if
used in an alternative protocol.
It is open to speculation what is the right exposure of
the LCs to corticosteroid to induce tolerance. Future
experiments with different potency of topical corticos-
teroids and titration of the optimal dose and the duration
of the treatment, together with tolerance assays to define
the mechanism of the reduction of T-cell proliferation
and IFN-c production, are necessary to answer this ques-
tion. Although murine models can be used to address
some of these questions and explore in vivo effects on tol-
erance induction35–37 murine epidermis is 1/10th of the
thickness of human skin, increasing the likelihood of sys-
temic absorption of steroid after topical therapy and
making comparisons with human skin using this
approach difficult. We have therefore instituted a clinical
trial to compare tolerance induction after intradermal
autoantigen administration with and without topical ster-
oid pre-conditioning in humans.
To our knowledge, this is the first study exploring the
effect of topical steroid on the functioning of LCs,
through three different, but concordant, translational and
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Figure 5. Phenotype of blister-roof-derived Langerhans cells (LCs) with and without ex vivo exposure to betamethasone dipropionate cream
(005% w/w). The effect of topical corticosteroid was assessed by the measurement of the expression of surface markers, illustrated by mean fluo-
rescence intensity (MFI) measure by flow cytometry, of CD80 (n = 7, ns), CD86 (n = 7, P = 004), CD83 (n = 7, P = 004), HLA-DR (n = 7,
ns) and immunoglobulin-like transcript 3 (ILT-3) (n = 7, ns). *P < 005; ns, not statistically significant.
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clinical models. Taken together, our experiments, suggest
that topical pre-conditioning of the skin with steroid for
1–4 days modulates LCs by blunting their pro-inflamma-
tory signals and potentially enhancing tolerance. Although
these findings require confirmation in clinical trials, we
suggest that steroid pre-treatment before the injection of
antigens for antigen-specific immunotherapy might pro-
vide an inexpensive, readily available and safe adjunct to
current approaches to treat autoimmune disease.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Viability of Langerhans cells (LCs) in the
ex vivo human skin organ culture.
Figure S2. Viability of Langerhans cells (LCs) in the
blister roof.
Figure S3. Effect of other topical agents (calcipotriol
0005% w/w, calcipotriol + betamethasone 0005% w/
w + 005% w/w and tretinoin 001% w/w) on blister fluid
and phenotype and function of blister-roof-derived
Langerhans cells (LCs).
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